Technology | Population Health | April 03, 2015

PatientPoint Population Health Management Application Receives Meaningful Use Certification

Software provides automated outreach from physicians to patients

April 3, 2015 — PatientPoint announced that PatientPoint Outreach 3.2 is now certified for Meaningful Use in an ambulatory setting. The software is also compliant with the Office of the National Coordinator (ONC) 2014 Edition criteria for certified electronic health record technology (CEHRT).

The ONC 2014 Edition criteria supports both Stage 1 and Stage 2 Meaningful Use measures that are required to qualify eligible providers for funding under the American Recovery and Reinvestment Act (ARRA).

PatientPoint Outreach 3.2 provides trusted and secure communications on behalf of the physician, and is highly customizable to a provider’s goals. By helping to manage patient adherence and follow-up, it can play a key role in improving clinical outcomes throughout the care continuum.

Driven by a population health analytics engine, the software provides automated outreach by email, text and interactive voice response (IVR), depending on the patient's stated preference. Eligible providers can submit against the Stage 1 and Stage 2 criteria for patient list creation and patient reminders.

PatientPoint Outreach 3.2 was certified by the Certification Commission for Health Information Technology (CCHIT) in accordance with the applicable Eligible Provider certification criteria adopted by the Secretary of Health and Human Services. PatientPoint certification (#IG-3251-15-0016) meets the following criteria:

  • 170.314(a)(14) Patient List Creation and Reminders
  • 170.314(g)(2) Automated Measures
  • 170.314(g)(4) Quality Management System

 

The application was certified by Infogard, an Accredited Testing Laboratory (NVLAP Lab Code: 100432-0) and ONC-Authorized Certification Body to test and certify Electronic Health Record (EHR) products for the ONC HIT Certification Program. InfoGard provides information technology services for organizations within the healthcare, financial, and federally mandated markets.

For more information: www.patientpoint.com

Related Content

EMPRISE Study Shows Empagliflozin Reduces Heart Failure Hospitalization with new data presented at AHA 2018. #AHA18 #AHA2018
News | Heart Failure | November 07, 2018
November 6, 2018 – Initial results from the real-world EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) s
Acute Heart Failure Mortality, Rehospitalizations Reduced With Blood Volume Measurement
News | Heart Failure | November 02, 2018
In a new study, acute heart failure patients who received individualized treatment by blood volume measurement with the...
Daxor Corp. Collaborating With CHF Solutions on Heart Failure Fluid Overload Management

CHF Solutions' Aquadex FlexFlow System

News | Heart Failure | November 01, 2018
November 1, 2018 — Daxor Corp.
NHLBI Pauses CONCERT-HF Heart Failure Trial
News | Heart Failure | October 29, 2018
The National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health, is pausing the...
A patient who received the HeartMate III LVAD system showing off his external battery pack. He served as a patient ambassador in the Abbott booth at ACC 2018. The HeartMate III, with its magnetic levitated pump, showed a big reduction in clotting over previous LVADs in a key late-breaking trial at ACC earlier this year.

A patient who received the HeartMate III LVAD system showing off his external battery pack. He served as a patient ambassador in the Abbott booth at ACC 2018. The HeartMate III, with its magnetic levitated pump, showed a big reduction in clotting over previous LVADs in a key late-breaking trial at ACC earlier this year.

Feature | Heart Failure | October 19, 2018
October 19, 2018 — Abbott announced today that the HeartMate 3 Left Ventricular Assist Device (LVAD) has received U.S
Ohio State First in U.S. to Test Shunt Device for Heart Failure
News | Heart Failure | October 04, 2018
The Ohio State University Wexner Medical Center is first in the country to test a new medical device designed to help...
Mitral Regurgitation Volume Reduced at One Year in REDUCE FMR Trial
News | Heart Failure | September 28, 2018
Heart failure patients who received the Carillon Mitral Contour System in the REDUCE FMR clinical trial showed a...
Overlay Init